Literature DB >> 10602494

Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B.

P Smart1, E B Lane, D P Lane, C Midgley, B Vojtesek, S Laín.   

Abstract

p53 tumour suppressor protein levels and p53-dependent transcriptional activity have been recently shown to increase in cells treated with leptomycin B (LMB), an inhibitor of nuclear export. Experiments presented here show that LMB treatment leads to growth arrest and a senescence-like phenotype in human normal fibroblast cultures. This effect is reversible after removal of the drug and further passage by trypsinization. Instead, LMB has a strong cytotoxic effect on human neuroblastoma cell lines even at nanomolar concentrations. In both these cell types the effects of LMB are attenuated when the activity of the endogenous wild type p53 protein is abrogated by overexpression of a dominant negative p53 mutant. We conclude that the induction of the p53 response by LMB plays an important role in the effects of this drug on cultured cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10602494     DOI: 10.1038/sj.onc.1203260

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  C-terminal ubiquitination of p53 contributes to nuclear export.

Authors:  M A Lohrum; D B Woods; R L Ludwig; E Bálint; K H Vousden
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

2.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.

Authors:  Kensuke Kojima; Marina Konopleva; Ismael J Samudio; Masato Shikami; Maria Cabreira-Hansen; Teresa McQueen; Vivian Ruvolo; Twee Tsao; Zhihong Zeng; Lyubomir T Vassilev; Michael Andreeff
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

3.  Activation of p53 in cervical carcinoma cells by small molecules.

Authors:  S Hietanen; S Lain; E Krausz; C Blattner; D P Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

4.  p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.

Authors:  D A Tweddle; A J Malcolm; M Cole; A D Pearson; J Lunec
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 5.  p53-based cancer therapy.

Authors:  David P Lane; Chit Fang Cheok; Sonia Lain
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05-12       Impact factor: 10.005

Review 6.  Strategies for manipulating the p53 pathway in the treatment of human cancer.

Authors:  T R Hupp; D P Lane; K L Ball
Journal:  Biochem J       Date:  2000-11-15       Impact factor: 3.857

Review 7.  Reviving the guardian of the genome: Small molecule activators of p53.

Authors:  Daniel Nguyen; Wenjuan Liao; Shelya X Zeng; Hua Lu
Journal:  Pharmacol Ther       Date:  2017-03-27       Impact factor: 12.310

8.  Identification of nuclear export inhibitors with potent anticancer activity in vivo.

Authors:  Sarah C Mutka; Wen Qing Yang; Steven D Dong; Shannon L Ward; Darren A Craig; Pieter B M W M Timmermans; Sumati Murli
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

Review 9.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

10.  Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

Authors:  Sonia Lain; Jonathan J Hollick; Johanna Campbell; Oliver D Staples; Maureen Higgins; Mustapha Aoubala; Anna McCarthy; Virginia Appleyard; Karen E Murray; Lee Baker; Alastair Thompson; Joanne Mathers; Stephen J Holland; Michael J R Stark; Georgia Pass; Julie Woods; David P Lane; Nicholas J Westwood
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.